Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.26 EUR | +3.90% | -1.39% | -1.39% |
06-27 | Guggenheim Initiates SOPHiA GENETICS at Buy With $6 Price Target | MT |
06-24 | Sophia Genetics S. A. Launches New Residual Acute Myeloid Application | CI |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 900.4 | 132.3 | 306.8 | 299.4 | - | - |
Enterprise Value (EV) 1 | 635.1 | -29.03 | 183.5 | 243.5 | 290.5 | 308.8 |
P/E ratio | -10.6 x | -1.51 x | -3.86 x | -4.65 x | -5.23 x | -6.8 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 22.3 x | 2.78 x | 4.92 x | 3.8 x | 2.98 x | 2.34 x |
EV / Revenue | 15.7 x | -0.61 x | 2.94 x | 3.09 x | 2.89 x | 2.41 x |
EV / EBITDA | -9.36 x | 0.35 x | -2.76 x | -4.26 x | -6.77 x | -9.89 x |
EV / FCF | -10.5 x | 0.39 x | - | -4.1 x | -8.67 x | -18.6 x |
FCF Yield | -9.55% | 256% | - | -24.4% | -11.5% | -5.38% |
Price to Book | 3.27 x | 0.66 x | - | 2.86 x | 4.53 x | 5.95 x |
Nbr of stocks (in thousands) | 63,858 | 64,211 | 65,132 | 65,375 | - | - |
Reference price 2 | 14.10 | 2.060 | 4.710 | 4.580 | 4.580 | 4.580 |
Announcement Date | 15/03/22 | 07/03/23 | 05/03/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | 40.45 | 47.56 | 62.37 | 78.69 | 100.4 | 128.1 |
EBITDA 1 | - | -67.88 | -82.25 | -66.49 | -57.22 | -42.89 | -31.24 |
EBIT 1 | - | -71.49 | -87.82 | -74.83 | -62.53 | -50.03 | -39.12 |
Operating Margin | - | -176.73% | -184.66% | -119.97% | -79.46% | -49.82% | -30.53% |
Earnings before Tax (EBT) 1 | - | -73.51 | -87.58 | -78.5 | -62.62 | -55.69 | -42.55 |
Net income 1 | -39.34 | -73.68 | -87.45 | -78.98 | -64.4 | -57.76 | -44.14 |
Net margin | - | -182.14% | -183.87% | -126.63% | -81.83% | -57.52% | -34.46% |
EPS 2 | -0.9300 | -1.330 | -1.360 | -1.220 | -0.9850 | -0.8750 | -0.6733 |
Free Cash Flow 1 | - | -60.62 | -74.19 | - | -59.4 | -33.5 | -16.6 |
FCF margin | - | -149.87% | -155.99% | - | -75.49% | -33.36% | -12.96% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 24/05/21 | 15/03/22 | 07/03/23 | 05/03/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 10.94 | 10.86 | 11.67 | 11.65 | 13.38 | 13.97 | 15.05 | 16.3 | 17.05 | 15.78 | 17.4 | 21.5 | 23.79 | 21.32 | 23.13 |
EBITDA 1 | -19.78 | -23.83 | -22.69 | -22.19 | -13.53 | -17.4 | -17.78 | -14.34 | -16.96 | - | -18.7 | -12.8 | -13.7 | -10.9 | -12.3 |
EBIT 1 | -21.01 | -25.02 | -24.08 | -23.64 | -15.08 | -19.29 | -20.05 | -16.54 | -18.95 | -18.76 | -16.65 | -13.49 | -12.59 | -14.06 | -12.99 |
Operating Margin | -192.09% | -230.37% | -206.39% | -202.94% | -112.69% | -138.1% | -133.17% | -101.48% | -111.13% | -118.87% | -95.71% | -62.77% | -52.91% | -65.93% | -56.16% |
Earnings before Tax (EBT) 1 | -21.9 | -25.25 | - | -23.42 | -14.23 | -19.59 | -21.32 | -13.52 | -24.05 | -13.39 | -19.19 | -15.42 | -14.61 | -15.52 | -14.13 |
Net income 1 | -21.37 | -25.49 | - | -23.31 | -13.97 | -19.7 | -21.4 | -13.82 | -24.06 | -13.7 | -19.25 | -15.48 | -14.67 | -15.56 | -14.17 |
Net margin | -195.43% | -234.67% | - | -200.12% | -104.39% | -141.06% | -142.13% | -84.79% | -141.13% | -86.85% | -110.67% | -72% | -61.66% | -73% | -61.24% |
EPS 2 | -0.3300 | -0.4000 | -0.3900 | -0.3600 | -0.2200 | -0.3100 | -0.3300 | -0.2100 | -0.3700 | -0.2100 | -0.2925 | -0.2450 | -0.2350 | -0.2433 | -0.2267 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 15/03/22 | 10/05/22 | 09/08/22 | 08/11/22 | 07/03/23 | 09/05/23 | 08/08/23 | 07/11/23 | 05/03/24 | 07/05/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - | 9.4 |
Net Cash position 1 | - | 265 | 161 | 123 | 56 | 8.9 | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | -0.3009 x |
Free Cash Flow 1 | - | -60.6 | -74.2 | - | -59.4 | -33.5 | -16.6 |
ROE (net income / shareholders' equity) | - | -39.2% | -36.8% | -44.9% | -53.1% | -74.8% | -80.8% |
ROA (Net income/ Total Assets) | - | -32.6% | -31% | - | - | - | - |
Assets 1 | - | 226.1 | 282 | - | - | - | - |
Book Value Per Share 2 | - | 4.310 | 3.120 | - | 1.600 | 1.010 | 0.7700 |
Cash Flow per Share | - | - | -1.090 | - | - | - | - |
Capex 1 | - | 2.68 | 4.1 | 1.49 | 3.3 | 1 | 1 |
Capex / Sales | - | 6.63% | 8.61% | 2.4% | 4.19% | 1% | 0.78% |
Announcement Date | 24/05/21 | 15/03/22 | 07/03/23 | 05/03/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.86% | 3,322B | |
+15.57% | 91.17B | |
+12.99% | 84.37B | |
+47.52% | 56.41B | |
-20.20% | 49.69B | |
+35.77% | 47.79B | |
-25.64% | 46.04B | |
+76.35% | 41.02B | |
-3.39% | 27.21B |
- Stock Market
- Equities
- SOPH Stock
- 90B Stock
- Financials SOPHiA GENETICS SA